A novel case study on safety and efficacy profile of intralesional vitamin D3 in the treatment of multiple cutaneous warts

Immunotherapy has now become one of the emerging therapeutic tools for treatment of multiple warts. In this case series we tried to analyse the safety and efficacy profile of intralesional vitamin D3, a novel immunotherapeutic agent. A total of 24 patients between 12 to 60 years having more than 3 cutaneous warts were included. Four patients lost follow up and 20 patients were studied. Each patient received 0.1 ml of vitamin D3 (15 mg/ml, 6l IU/ml) injected intralesionally into one wart, with a maximum of 5 warts treated. The injection is repeated 2 weeks once until complete resolution or total of 4 injections. The primary outcome measure is complete resolution of warts and return of normal skin markings. Out of 20 patients, 15 (75%) showed complete clearance. One patient showed recurrence during follow up period. Adverse effects are all minimal including erythema, induration and pain at the injection site. Injection vitamin D3 is a safer, inexpensive, easily available and effective immunotherapeutic agent for treatment of multiple warts. The injection site must be carefully selected to avoid disfiguring induration.